Apollomics Inc Cl A (APLM) Stock Price, Quote & News

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule mu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 209 4055

Fax: 650 288 1674

Website: www.apollomicsinc.com

Address:

989 East Hillsdale Blvd., Suite 220, Foster City, United States

lars70 Jun. 6 at 10:49 PM

$APLM Im a buyer at 13 14 15

0 · Reply

SuperGreenToday Jun. 4 at 3:52 PM

$APLM

0 · Reply

AtlasAnalysis Apr. 16 at 2:24 PM

$APLM glued to support. Volume or catalyst turns it around to 20+

0 · Reply

DARKP00L Apr. 1 at 11:13 AM

$APLM 07:11 on Apr. 01 2026 Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30 #tradeideas

0 · Reply

EmergingMarketDebt Feb. 17 at 12:25 PM

$APLM Obscure micro-cap; likely a shell with negligible operations.

0 · Reply

BSMARKET Jan. 14 at 3:03 PM

$APLM $THH $ANPA

0 · Reply

BSMARKET Jan. 13 at 11:52 PM

$APLM will follow $THH $ANPA same territory

0 · Reply

SuperGreenToday Dec. 31 at 4:13 PM

$APLM

0 · Reply

caprihunter Dec. 29 at 3:44 PM

$MMA $HIT.X $CABR $APLM $PRAX

0 · Reply

RiskPoolingR Dec. 25 at 7:59 AM

$APLM Market tolerance narrows as uncertainty lingers, while management calibrates resource allocation to real demand signals. Clear follow‑through could unlock sustainable re‑rating.

0 · Reply

Apollomics Registration statement: Registration filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apr 27, 2026, 7:00 AM EDT - 6 weeks ago

Apollomics Annual report: Q4 2025

Apr 27, 2026, 7:00 AM EDT - 6 weeks ago

Apollomics Earnings release: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 2 months ago

Apollomics Inc. Announces $2.0 Million Bridge Financing

2026-03-09T21:20:09.000Z - 3 months ago

Apollomics files to sell 279,775 Class A Ordinary shares for holders

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Apollomics Registration statement: Registration Filing

2025-12-30T21:00:11.000Z - 5 months ago

Apollomics Inc trading resumes

2025-12-30T20:55:19.000Z - 5 months ago

Apollomics Inc trading halted, volatility trading pause

Dec 22, 2025, 4:05 PM EST - 6 months ago

Apollomics Reports First Half 2025 Financial Results

Dec 22, 2025, 3:00 PM EST - 6 months ago

Apollomics Earnings release: Q2 2025

2025-11-21T16:50:25.000Z - 7 months ago

Apollomics Inc trading resumes

2025-11-21T16:45:23.000Z - 7 months ago

Apollomics Inc trading halted, volatility trading pause

2025-11-19T22:45:12.000Z - 7 months ago

Apollomics announces settlement of Cayman litigation

Nov 19, 2025, 5:38 PM EST - 7 months ago

Apollomics Announces Settlement of Cayman Litigation

2025-11-18T16:15:24.000Z - 7 months ago

Apollomics Inc trading resumes

2025-11-18T16:10:11.000Z - 7 months ago

Apollomics Inc trading halted, volatility trading pause

Nov 17, 2025, 11:00 PM EST - 7 months ago

Apollomics Announces Changes to its Board of Directors and Composition of Committees

2025-10-31T14:11:03.000Z - 8 months ago

Apollomics Inc trading resumes

2025-10-31T14:06:22.000Z - 8 months ago

Apollomics Inc trading halted, volatility trading pause

2025-10-16T17:15:20.000Z - 8 months ago

Apollomics Inc trading resumes

2025-10-16T17:10:24.000Z - 8 months ago

Apollomics Inc trading halted, volatility trading pause

2025-10-15T18:45:14.000Z - 8 months ago

Apollomics says securities to remain listed on Nasdaq

Oct 15, 2025, 2:36 PM EDT - 8 months ago

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

2025-10-14T20:10:22.000Z - 8 months ago

nasdaq resumes trading in Apollomics

2025-10-14T10:00:33.000Z - 8 months ago

Apollomics reverses wind-up plans, provides operational update

Oct 13, 2025, 9:22 PM EDT - 8 months ago

Apollomics, Inc. Company Operational Continuity Update

2025-09-17T21:56:00.000Z - 9 months ago

Nasdaq halts Apollomics

NDAQ

2025-05-23T18:25:25.000Z - 1 year ago

Apollomics Inc trading resumes

2025-05-23T18:20:12.000Z - 1 year ago

Apollomics Inc trading halted, volatility trading pause

2025-04-15T14:04:48.000Z - 1 year ago

Apollomics Inc trading resumes

2025-04-15T13:51:02.000Z - 1 year ago

Apollomics Inc trading halted, volatility trading pause

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

$Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Dec 20, 2024, 8:00 AM EST - 1 year ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 10, 2024, 4:05 PM EST - 1 year ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 10:00 AM EDT - 1 year ago

Apollomics Earnings release: Q2 2024

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Jul 16, 2024, 4:47 PM EDT - 2 years ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

May 20, 2024, 8:00 AM EDT - 2 years ago

Apollomics Registration statement: Registration Filing

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Apollomics Registration statement: Registration Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Apollomics Registration statement: Registration Filing

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Apollomics Registration statement: Registration Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Apollomics Registration statement: Registration Filing

Mar 28, 2024, 12:00 PM EDT - 2 years ago

Apollomics Annual report: Q4 2023

Mar 28, 2024, 12:00 PM EDT - 2 years ago

Apollomics Earnings release: Q4 2023

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 4, 2024, 7:00 AM EST - 2 years ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Feb 7, 2024, 7:00 AM EST - 2 years ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 19, 2024, 4:15 PM EST - 2 years ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 17, 2024, 4:30 PM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

$Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia$

Jan 3, 2024, 7:00 AM EST - 2 years ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 2, 2024, 4:30 PM EST - 2 years ago

Apollomics to Present at the 2024 Biotech Showcase

Nov 29, 2023, 7:30 AM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 28, 2023, 7:00 AM EST - 2 years ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 16, 2023, 8:30 AM EST - 2 years ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 11:00 AM EDT - 2 years ago

Apollomics Earnings release: Q2 2023

Sep 6, 2023, 7:00 AM EDT - 3 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Jul 7, 2023, 8:00 AM EDT - 3 years ago

Apollomics Registration statement: Registration Filing

Jun 9, 2023, 8:00 AM EDT - 3 years ago

Apollomics Registration statement: Registration Filing

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Jan 13, 2023, 4:13 PM EST - 3 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Oct 7, 2022, 4:05 PM EDT - 4 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

lars70 Jun. 6 at 10:49 PM

$APLM Im a buyer at 13 14 15

0 · Reply

SuperGreenToday Jun. 4 at 3:52 PM

$APLM

0 · Reply

AtlasAnalysis Apr. 16 at 2:24 PM

$APLM glued to support. Volume or catalyst turns it around to 20+

0 · Reply

DARKP00L Apr. 1 at 11:13 AM

$APLM 07:11 on Apr. 01 2026 Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30 #tradeideas

0 · Reply

EmergingMarketDebt Feb. 17 at 12:25 PM

$APLM Obscure micro-cap; likely a shell with negligible operations.

0 · Reply

BSMARKET Jan. 14 at 3:03 PM

$APLM $THH $ANPA

0 · Reply

BSMARKET Jan. 13 at 11:52 PM

$APLM will follow $THH $ANPA same territory

0 · Reply

SuperGreenToday Dec. 31 at 4:13 PM

$APLM

0 · Reply

caprihunter Dec. 29 at 3:44 PM

$MMA $HIT.X $CABR $APLM $PRAX

0 · Reply

RiskPoolingR Dec. 25 at 7:59 AM

$APLM Market tolerance narrows as uncertainty lingers, while management calibrates resource allocation to real demand signals. Clear follow‑through could unlock sustainable re‑rating.

0 · Reply

TonySuprano Dec. 16 at 8:36 PM

$APLM

0 · Reply

DARKP00L Dec. 12 at 5:00 PM

$APLM 11:43 on Dec. 12 2025 On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations #tradeideas

0 · Reply

TheRealBearKillaAlerts Dec. 11 at 1:48 PM

$APLM bullish move incoming! Chart is hot! 🚀

0 · Reply

Market Cap	31.42M
Revenue (ttm)	8.50M
Net Income (ttm)	-10.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-128.71%
Debt to Equity Ratio	0.00

Volume	15,800
Avg Vol	9,468
Day's Range	N/A - N/A
Shares Out	2.20M
Stochastic %K	57%
Beta	1.53
Analysts	Strong Buy
Price Target	$6.50